Candriam S.C.A. Acquires 1,358,068 Shares of Geron Corporation $GERN

Candriam S.C.A. boosted its holdings in shares of Geron Corporation (NASDAQ:GERN) by 71.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,253,960 shares of the biopharmaceutical company’s stock after purchasing an additional 1,358,068 shares during the quarter. Candriam S.C.A. owned about 0.51% of Geron worth $4,458,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GERN. Savant Capital LLC lifted its holdings in shares of Geron by 73.8% during the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 11,074 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in Geron by 204.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 34,238 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 22,993 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Geron during the 2nd quarter valued at $50,000. Walleye Capital LLC acquired a new position in Geron during the 2nd quarter valued at $56,000. Finally, Forefront Wealth Partners LLC bought a new stake in Geron in the 3rd quarter valued at $72,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Trading Down 0.6%

Shares of GERN opened at $1.61 on Thursday. The company has a current ratio of 5.96, a quick ratio of 4.87 and a debt-to-equity ratio of 0.48. The stock has a market cap of $1.03 billion, a PE ratio of -13.42 and a beta of 0.62. Geron Corporation has a 1 year low of $1.04 and a 1 year high of $2.84. The stock has a 50 day simple moving average of $1.37 and a 200-day simple moving average of $1.31.

Wall Street Analysts Forecast Growth

GERN has been the topic of several research reports. UBS Group restated a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. HC Wainwright restated a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. TD Cowen reiterated a “buy” rating on shares of Geron in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a report on Wednesday, January 28th. Finally, Needham & Company LLC lowered their price objective on Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $2.75.

Geron Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.